The body's own antibiotic slowed gastric cancer in mice by shutting off an inflammation switch
LL-37 ↗ is the peptide your own skin, gut, and immune cells make to punch holes in bacteria. It is the human cathelicidin, a short antimicrobial chain that is part of the innate immune system's first response to infection. A new study puts it in a different job. In gastric cancer cells and in mice, LL-37 slowed the tumor's ability to build a blood supply and to spread, and the authors traced the effect to a single inflammatory circuit the cancer relies on.
The work, published in Histology and Histopathology ↗ by groups in Guiyang and Huanggang, tested LL-37 across five gastric cancer cell lines: HGC27, MKN74, AGS, HSC-39, and NCI-N87. The peptide cut how many cells survived and lowered two signals the tumor uses to grow. One was interleukin-6, an inflammatory messenger. The other was VEGFA, the protein tumors release to recruit new blood vessels. With less of those two signals present, the cancer cells formed fewer vessel-like tubes in a dish, migrated less, and invaded less. LL-37 also blunted the pro-spreading effects normally triggered by TGF-beta, a growth factor that pushes cancer cells toward a mobile, invasive state.
The mechanism is where the study earns its title. Nuclear factor kappa B, usually shortened to NF-kB, is a master switch that turns on inflammation genes, including the gene for interleukin-6. To fire, its p65 subunit gets chemically tagged, moves into the cell nucleus, and lands on the promoter, the on-switch region, of its target genes. LL-37 interrupted every step of that sequence. It reduced the tagging of p65, kept p65 out of the nucleus, and cut how much p65 bound the interleukin-6 promoter. When the researchers forced the cells to overproduce interleukin-6, the anti-cancer effect went away. That kind of rescue experiment argues the peptide really is working through that circuit rather than beside it. A separate chemical that blocks NF-kB, BAY 11-7082, reproduced what LL-37 did.
In nude mice, animals bred to accept human tumor grafts, LL-37 treatment reduced spread to the lungs and lowered interleukin-6, VEGFA, and the active form of p65 inside the grafted tumors. So the same fingerprints the researchers found in a dish showed up in the animals.
Now the caution, because it is large. LL-37 is a two-faced molecule in cancer. The authors themselves call its role context-dependent, and the literature backs that up. In some tumors, including breast, lung, and ovarian cancer, LL-37 has been reported to help cancer grow, not slow it. A peptide that suppresses one cancer through NF-kB and feeds another through different receptors is not an obvious drug, and this study does not resolve that tension. It shows what LL-37 does to gastric cancer cells and to mouse grafts, and nothing more. There is no human here, no dosing, no delivery method for getting a peptide that bacteria and enzymes chew up to a tumor intact, and the report sits in a specialist histology journal rather than a major oncology title.
What makes it worth a note is the contrast with the peptide's day job ↗. The molecule the body evolved to kill microbes turns out, in the right tissue, to also press on the inflammation switch that a stomach tumor uses to feed and spread itself. That does not make LL-37 an anticancer ↗ drug. It makes the overlap between the immune ↗ system's antimicrobial toolkit and cancer signaling one more place worth looking, with the reminder that the same peptide can read as protective in one organ and dangerous in another.